The priority in the treatment of low-risk myelodysplastic syndrome (MDS) is managing cytopenia, primarily anemia, as well as neutropenia and thrombocytopenia. The following summary of recommendations sets the criteria for response to treatment and lists current therapeutic options for the 1st and 2nd lines.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
